Post hoc analysis: 6 Months immunogenicity after third dose of BNT162b2 vs JNJ-78,436,735 after two doses of BNT162b2 vaccine in solid organ transplant recipients.

• Tác giả: Shweta Anjan, Leopoldo Arosemena, Julia Bini, George William Burke, Jessie Chen, Giselle Guerra, Suresh Manickavel, Eric Martin, Adela Mattiazzi, Mrudula R Munagala, Yoichiro Natori, Suresh Pallikkuth, Jacques Simkins, Katherine Sota, Rodrigo M Vianna
• Ngôn ngữ: eng
• Thông tin xuất bản: Netherlands : Immunology letters , 2025
• Bộ sưu tập: NCBI
• ID: 60485

Tóm tắt

 INTRODUCTION: In Solid Organ Transplant (SOT) recipients, due to immunosuppression, the immunogenicity after COVID-19 vaccination is suboptimal and its durability is unknown. METHODS: We conducted a post-hoc analysis of a patient-blinded, single center, randomized controlled trial comparing BNT162b2 vs JNJ-78,436,735 as the third dose after two doses of BNT162b2 in adult SOT recipients with active graft to compare long-term immunogenicity. RESULTS: Forty-one recipients were analyzed. Median IgG levels against SARS-CoV-2 at 6 months were 53,747 (range 949 - 657,558) and 7,632 (range 642 - 672,000) AU/ml for BNT162b2 vs JNJ-78,436,735, respectively (p = 0.017). The median geometric mean fold increase ratio at 6 months was 37.2 (0.12-618.5) and 4.30 (0.1-204.2) for BNT162b2 vs JNJ-78,436,735, respectively (p <
  0.05). After two doses of BNT162b2, homologous approach with BNT162b2 achieved a superior immunogenicity compared to heterologous approach with JNJ-78,436,735. CONCLUSION: In this post hoc analysis, we report durability of specific IgG between two vaccine strategies and found no statistically significant difference between two groups. (Clinical Trial Registry: NCT05047640).